Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 anifrolumab study in active proliferative lupus nephritis
NL-OMON60527Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing Anifrolumab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Complete renal response at Week 52. Started Jul 2022; status: active, not recruiting.
02
Drugs
anifrolumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON60527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60527.